CLAIM #48456 · Pfizer Inc (PFE) · 2024Q3 earnings call · Oct 29, 2024 · due Apr 29, 2025
“We're also planning to start the combination of sicotatactedotin pembrolizumab in the first-line setting of non-small cell lung cans and recently discussed and aligned with the FDA on trial design and on the dosing.”
Chris Boshoff · Chief Oncology Officer
CANNOT_DETERMINE
resolved by a revision, graded at the moved level · official band 5 percent
Committed
We're also planning to start the combination of sicotatactedotin pembrolizumab in the first-line setting of non-small cell lung cans and recently discussed and aligned with the FDA on trial design and on the dosing.
Reported
We also anticipate a first-line pivotal study start for SV Sigmata top with doctor.
Verify independently
SEC filings for PFE ↗ · Claim quote is verbatim from the 2024Q3 earnings call.